Few clinical and molecular factors have been studied, such as CD133 overexpression and platinum resistance [17], overexpression of MDR-1 (multi drug resistance 1) [18], having suffered from a previous breast cancer [19], loss of BRCA function [20] and, presence of mutations in BRCA1 and BRCA2 genes [21]. This evidence concerns the gene BRCA2 and breast cancer.